Related Experiment Video

Updated: Feb 26, 2026

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

7.4K

Mesothelioma: recent highlights

Michele Carbone1, Haining Yang1

  • 1Thoracic Oncology, University of Hawaii Cancer Center, Honolulu, HI 96816, USA.

Annals of Translational Medicine
|July 15, 2017
PubMed

Insights

Discoveries reveal chronic inflammation and BAP1 gene mutations drive mesothelioma. High mobility group box protein-1 (HMGB1) and other biomarkers may revolutionize early detection and treatment for asbestos-related cancers.

Area of Science:

  • Oncology
  • Genetics
  • Environmental Health

Background:

  • Mesothelioma development mechanisms are increasingly understood.
  • Chronic inflammation and genetic predispositions are implicated in its pathogenesis.
  • Asbestos exposure remains a primary risk factor.

Purpose of the Study:

  • To elucidate key molecular and genetic mechanisms in mesothelioma development.
  • To highlight the role of chronic inflammation and specific gene mutations.
  • To identify novel biomarkers for improved screening and treatment.

Main Methods:

  • Review of recent discoveries in mesothelioma research.
  • Analysis of the role of high mobility group box protein-1 (HMGB1) in inflammation.
  • Investigation of germline BRCA-associated protein 1 (BAP1) mutations and their interaction with environmental factors.

Main Results:

  • Chronic inflammation, driven by HMGB1 release post-asbestos exposure, promotes mesothelioma.
  • Germline BAP1 mutations significantly increase mesothelioma incidence and lower asbestos exposure thresholds.
  • HMGB1 and Fibulin-3 identified as potential serum biomarkers.

Conclusions:

  • Understanding inflammation and BAP1 mutations is crucial for mesothelioma pathogenesis.
  • Novel biomarkers like HMGB1 and Fibulin-3 show promise for revolutionizing screening and treatment.
  • Gene-environment interactions, particularly BAP1 and asbestos, are critical in mesothelioma development.
Keywords:
BRCA-associated protein 1 (BAP1)MesotheliomaSV40asbestoserionitehigh mobility group box protein-1 (HMGB1)

More Related Videos

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

2.3K
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.7K

Related Concept Videos

Pleural Disorders: Types and Brief Description01:30

Pleural Disorders: Types and Brief Description

The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
795
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.7K
Toxic Reactions: Overview01:26

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
2.9K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K